SuperGen, Inc. to Present at UBS Warburg Global Life Sciences Conference September 26

DUBLIN, Calif., Sept. 19 /PRNewswire-FirstCall/ -- SuperGen Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that James S. Manuso, Ph.D., President and Chief Executive Officer is scheduled to present at the UBS Global Life Sciences Conference on September 26, 2007, at The Grand Hyatt New York.

SuperGen's presentation at the UBS Global Life Sciences Conference is scheduled to begin at 2:30 p.m. EDT. A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com. The webcast will be archived for 90 days.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Contacts Timothy L. Enns Mary M. Vegh SuperGen, Inc. SuperGen, Inc. SVP, Corporate Communications Manager, Investor Relations & Business Development Tel: (925) 560-0100 Tel: (925) 560-2845 E-mail: tenns@supergen.com E-mail: mary.vegh@supergen.com

SuperGen Inc.

CONTACT: Timothy L. Enns, SVP, Corporate Communications & BusinessDevelopment, +1-925-560-0100, tenns@supergen.com, or Mary M. Vegh, Manager,Investor Relations, +1-925-560-2845, mary.vegh@supergen.com, both ofSuperGen, Inc.

Back to news